Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;3(2):321-31.
doi: 10.1007/s40121-014-0050-x. Epub 2014 Dec 3.

Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection

Nicholas S Britt  1   2   3 , Molly E Steed  4 , Emily M Potter  5 , Lisa A Clough  6
Affiliations

Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection

Nicholas S Britt et al. Infect Dis Ther. 2014 Dec.

Abstract

Introduction: Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhea. Metronidazole and vancomycin are the primary treatment options for CDI, but increasing rates of antimicrobial resistance and severe, refractory disease have prompted the need for alternative agents. Tigecycline has previously demonstrated favorable in vitro activity against C. difficile isolates, but clinical data on its use in the treatment of CDI are severely lacking. The objective of this study was to describe our experience using tigecycline in the treatment of severe and severe complicated CDI.

Methods: This was a retrospective case series of hospitalized patients with severe and severe complicated CDI who were treated with tigecycline. Disease severity assessments were determined according to current practice guidelines. Diagnosis of toxigenic CDI was confirmed by polymerase chain reaction and patients were excluded if they received tigecycline for <48 h. Data were collected by review of the electronic medical record. The primary outcome was clinical cure. Secondary outcomes were sustained response, hospital mortality, and 28-day all-cause mortality.

Results: A total of 7 cases of severe and complicated CDI were reviewed. Intravenous tigecycline administered as a 100-mg loading dose followed by 50 mg twice daily resulted in clinical cure in 85.7% (n = 6/7) of cases. The majority of patients (n = 4/5) were treated with the novel triple therapy combination of tigecycline, vancomycin, and metronidazole and resulted in clinical cure in 80% (n = 4/5) cases. Sustained response at 28 days was 100% among evaluable cases (n = 5/5). Hospital mortality did not occur in any patients, and 28-day all-cause mortality was 28.6% (n = 2/7).

Conclusion: Tigecycline appears to be a reasonable addition to the therapeutic regimen in the treatment of severe or complicated CDI, including cases that are refractory to standard therapy. A prospective clinical trial confirming these observational findings is warranted.

Keywords: Clostridium difficile; Combination drug therapy; Tigecycline.

PubMed Disclaimer

References

    1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infect Control Hosp Epidemiol. 2010;31(5):431–455. doi: 10.1086/651706. - DOI - PubMed
    1. Moudgal V, Sobel JD. Clostridium difficile colitis: a review. Hosp Pract (1995) 2012;40(1):139–148. doi: 10.3810/hp.2012.02.954. - DOI - PubMed
    1. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13(4):450–455. doi: 10.1097/MCC.0b013e3282638879. - DOI - PubMed
    1. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145(10):758–764. doi: 10.7326/0003-4819-145-10-200611210-00008. - DOI - PubMed
    1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. 2013. p. 55–9. http://www.cdc.gov/drugresistance/threat-report-2013/

LinkOut - more resources